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The aim of this study was to identify genetic variants associated with rheumatoid arthritis (RA) risk in black South Africans. Black
South African RA patients (n = 263) were compared with healthy controls (n = 374). Genotyping was performed using the Immunochip, and four-digit high-resolution human leukocyte antigen (HLA) typing was performed by DNA sequencing of exon 2.
Standard quality control measures were implemented on the data. The strongest associations were in the intergenic region between the HLA-DRB1 and HLA-DQA1 loci. After conditioning on HLA-DRB1 alleles, the effect in the rest of the extended major histocompatibility (MHC) diminished. Non-HLA single nucleotide polymorphisms (SNPs) in the intergenic regions LOC389203|RBPJ,
LOC100131131|IL1R1, KIAA1919|REV3L, LOC643749|TRAF3IP2, and SNPs in the intron and untranslated regions (UTR) of IRF1 and
the intronic region of ICOS and KIAA1542 showed association with RA (p < 5 × 10–5). Of the SNPs previously associated with RA in
Caucasians, one SNP, rs874040, locating to the intergenic region LOC389203|RBPJ was replicated in this study. None of the variants in the PTPN22 gene was significantly associated. The seropositive subgroups showed similar results to the overall cohort. The
effects observed across the HLA region are most likely due to HLA-DRB1, and secondary effects in the extended MHC cannot be
detected. Seven non-HLA loci are associated with RA in black South Africans. Similar to Caucasians, the intergenic region between LOC38920 and RBPJ is associated with RA in this population. The strong association of the R620W variant of the PTPN22
gene with RA in Caucasians was not replicated since this variant was monomorphic in our study, but other SNP variants of the
PTPN22 gene were also not associated with RA in black South Africans, suggesting that this locus does not play a major role in RA
in this population.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2014.00097

INTRODUCTION
Rheumatoid arthritis (RA) is a complex
autoimmune disease affecting 0.5% to 1%
of the population worldwide. This is
characterized by chronic inflammation of
synovial joints resulting in progressive
joint destruction. The etiology of RA re-

mains elusive; however it is thought to
occur in a genetically predisposed individual who is exposed to a set of environmental triggers. The heritability of RA is
estimated to be as high as 50% to 60% (1).
In recent years, genome-wide association studies (GWASs) have made great
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strides in identifying novel loci associated with RA. Despite these discoveries,
less than 50% of the heritability can be
explained. GWASs also have uncovered
that various autoimmune diseases share
similar risk loci (2). Thus, aggregating
diseases with similar pathogenesis is a
logical and cost effective method to identify associated loci that overlap various
autoimmune diseases. The Immunochip
consortium designed a genotyping array,
an Illumina Infinium array with ~196,000
single nucleotide polymorphisms (SNPs),
from 186 loci previously associated with
12 autoimmune diseases identified from
GWASs. The success of the Immunochip
is evidenced by novel risk loci, not previously associated with a specific pheno-
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type, being identified in numerous autoimmune diseases (3–8) including RA (9).
Genetic differences underlie the risk
for RA between the major ethnic groups.
The only genetic variants that have consistently been shown to confer a risk for
RA across all ethnic groups is the HLADRB1 alleles conferring a third of the genetic risk. The non-HLA genes, however,
show less consistency across ethnic
groups. The R620W variant of the
PTPN22 gene is strongly and consistently
associated with RA in Europeans (10,11)
but not in Asians or black South Africans
(12–14). In contrast, specific haplotypes
of the PADI4 gene confer risk for RA in
Asians (15–18) and less or no risk in Europeans (9,18–21). However a haplotype
in the STAT4 gene is associated with RA
in both Europeans and Asians (22,23).
Most large-scale genetic studies have
been done in Europeans and Asians, and
very few RA risk loci have been studied
in Africans. The strong association with
the HLA-DRB1 region has been replicated repeatedly (24–27). Ninety-two
percent of black South Africans with RA
carry at least one copy of the shared epitope alleles (27) which contrasts with
only ~30% in West Africans from
Cameroon (28), demonstrating significant heterogeneity within Africans.
To date, there has been no large-scale
genetic study performed on black
Africans with RA. In view of the observed heterogeneity between and within
ethnic groups, our aim was to examine
the role of known genetic loci previously
associated with RA and to identify novel
risk loci in black South Africans with RA.
MATERIALS AND METHODS
Consenting patients were recruited
from a single center, the Chris Hani
Baragwanath Academic Hospital, Soweto,
Johannesburg (n = 414). All patients were
unrelated and unselected, fulfilled the
American College of Rheumatology 1987
criteria for RA (29) and were over the age
of 18 years at disease onset. Patients were
considered as “black” South Africans if
they self reported all four grandparents as
being black South Africans. The controls

were geographically and ethnically
matched to the cases (n = 407). They were
recruited from the staff of the hospital or
from the outpatients department. These
were patients with minor trauma and no
history of inflammatory joint pain or autoimmune diseases. The study was approved by the Human Research Ethics
Committee (Medical) of the University of
the Witwatersrand (M10707).
Serology Tests
Rheumatoid factor (RF) (composite
IgM, IgG, IgA) was assayed by nephelometry (Siemens Healthcare Diagnostics, BN Prospec Nephelometer, Newark,
DE, USA). Anti-CCP (aCCP) was measured using a second-generation immunofluorimetric assay with the Immunocap 250 system and reagents and
controls provided by the manufacturer
(Phadia AB, Uppsala, Sweden). Rheumatoid factor and aCCP were considered
positive when the concentrations were
greater than 15 IU/mL and 10 U/mL, respectively.
Genotyping
Immunochip. Genotyping using the
Immunochip was performed at the Feinstein Institute for Medical Research, Manhasset, NY, USA. Genotype clustering
was performed using the default Illumina
cluster file (Immunochip_Gentrain_
June2010.egt) and manifest file (Immuno_
BeadChip_11419691.bpm) (NCBI build 36)
using the GenTrain2 clustering algorithm.
Genotype calling was done using the
Genotyping Module of the GenomeStudio
Data Analysis Software package. Markers with a significance for association of
p ≤ 5 × 10–5 were considered significant
(5) and the cluster plots were manually
inspected.
High resolution HLA DRB1 genotyping. Four-digit high resolution HLA typing was performed by DNA sequencing
of exon 2, using the AlleleSEQR HLA
DRB1 reagent kit and protocol (Atria Genetics, South San Franciso, CA, USA) at
the Division of Clinical Immunology and
Rheumatology, University of Alabama at
Birmingham, Birmingham, AL, USA.
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After polymerase chain reaction amplification of HLA DRB1 exon 2 from genomic DNA, forward and reverse cycle
sequencing was performed, and the resulting fragments were collected and analyzed on an ABI 377 automated sequencer (Applied Biosystems, Foster
City, CA, USA). An additional sequence
reaction was performed to analyze the
GTG (valine) motif of codon 86 sequences, thus enabling resolution of ambiguous results for some exon 2 sequences. The sequences were analyzed
using Assign software (Conexio Genomics, Fremantle, Western Australia,
Australia), which enables assignment of
genotypes based on a library file of HLADRB1 alleles (30). This method detects all
of the SE-positive alleles.
Quality control. Sample quality control
(QC) was done initially, followed by SNP
QC and population structure analysis.
Sample quality control included preprocessing of data in which poor performing
samples (genotype call rate <90%) were
removed. Thereafter, samples were excluded if the genotype missingness was ≥
6%, the recorded sex differed from the
genotype inferred sex, or if they were duplicated and related. Cryptic relatedness
was assessed by estimating identity by
state (IBS) statistic and an IBS > 0.95
PIHAT < 0.05 using PLINK v1.07, and
was used to exclude individuals. Only a
single pair of related individuals was
found with this cutoff and one of these
two individuals was randomly excluded
from further analysis. Single nucleotide
polymorphisms were excluded if the per
SNP missing genotype call rate was ≥5%
in either cases or controls, if they had a
strong difference in missingness among
cases and control (P < 10–3), they were
monomorphic or with a minor allele frequency (MAF) <0.05, the GenCall (GC)
score <0.15, they were sex chromosome
markers or duplicated markers or there
was extensive deviation from HardyWeinberg equilibrium (HWE) (p < 5 ×
10–7) in the controls (31).
Population structure was analyzed
using Eigenstat (32) structure and principal component (PC) analyses. The ge-
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nomic inflation factor in the final association test was found to be 1.14 (based on
median χ2 test). Plots were constructed
based on a comparison with HapMap 3
data (http://hapmap.ncbi.nlm.nih.gov/).
From the PC analysis (using the first five
principal components, weighted by
Eigenvalue), we computed the center of
the study group and computed the average distance of each individual to the center (average 0.0113). Individuals with a
distance greater than 0.017 were excluded
from the analysis. This cutoff was chosen
by plotting the distribution and choosing
the inflection point.
Statistical Analysis
The χ2 test was performed to determine differences in allele frequencies between patients and controls. Differences
were considered to be significant as follows: in the case of HLA loci p < 5 × 10–8
was used and, as defined previously, an
a priori significance threshold of p < 5 ×
10–5 was used for novel RA-associated
SNPs in this study (5) and p < 0.05 was
considered significant for replication.
Allele frequencies were compared between RA patients and controls by the
odds ratio (OR) with a 95% confidence
interval (CI). P values reported are from
2 × 2 contingency table analyses of
counts of minor and major alleles with
case-control status and were based on
the χ2 test or Fisher exact test. We also
used logistic regression to test single
marker association in the extended MHC
(Chr 6: 26 Mb to 34 Mb) after partialing
out the effects of variability explained by
HLA-DRB1. The model included as variables the number of copies of each HLADRB1 allele except for HLA-DRB1 11:01,
which was treated as the referent. In addition, the model included the number of
minor alleles of the extended MHC SNP
marker to be tested for association, conditional on the HLA-DRB1 alleles. These
conditional analyses were performed to
assess the independent effect of the risk
HLA-DRB1 alleles in the extended MHC.
All supplementary materials are available
online at www.molmed.org.

RESULTS
After quality control, 263 patients and
374 controls were tested for association
using 103,770 SNPs.
The majority of the cases were females
235/263 (89%) with a mean disease duration of 10.6 (SD = 7.3) years. Among
those tested, a high proportion were RF
(240/254) and aCCP (186/207) positive.
The ancestry informative markers and
principle component analyses (PCA)
showed a distinction between the black
South African RA cases and controls
from Caucasians (CEU), West Africans
that is, Yoruba of Nigeria (YRI) and the
East Africans, the Luhya (LWK) and
Maasai (MKK) tribes of Kenya (Supplementary Figure 2). The majority of the
samples formed a homogenous cluster;
however, some of the cases and controls
showed admixture with two other populations encountered in South Africa,
namely representative populations for
Caucasians and Gujarati Indians, and
were excluded from the analysis (33).
Thirty seven samples (5 controls and 32
cases) were therefore excluded in the
associations analyses based on these
findings.
HLA Associations
In total, 77 SNPs reached genome-wide
significance (p < 5 × 10–8) in this study
(Figure 1), most of which were in the
HLA region on chromosome 6. The
strongest associations were with one SNP
in the intronic region of the HLA-DRB5
(rs34083746, OR = 6.15, p = 1.31 × 10–25)
gene and three SNPs in the intergenic region HLA DRB1|HLA DQA1 (rs3104413,
OR = 3.88, p = 5.49 × 10–21; rs3129769,
OR = 3.91, p = 4.60 × 10–21; rs6931277,
OR = 3.97, p = 1.03 × 10–21). Of the significantly associated SNPs on chromosome 6,
60 SNPs locate to the HLA DR or DQ regions or the intergenic region between
these two genes and 10 SNPs located to
genes outside the HLA class II region on
chromosome 6 (HLA-associated genes)
(Supplementary Table 1).
Four HLA DRB1 alleles were associated
with a risk for RA in black South Africans
(*0401, OR = 4.0 [2.5–6.5], p < 0.0001);

*0404, OR = 6.9 [3.9–12.2], p < 0.0001;
*0405, OR = 4.96 [1.6–15.2], p = 0.0018);
*1001, OR = 1.8 [1.0–3.3], p = 0.039). Three
alleles conferred protection for RA (*1101,
OR = 0.5 [0.4–0.8], p = 0.0008); *1301, OR =
0.6 [0.4–0.8], p = 0.004; *1302, OR = 0.6
[0.4–1.0], p = 0.06) (Table 1). The correlation coefficient for the effect sizes of the
significantly associated alleles between
Europeans and black South Africans was
0.61 (Supplementary Figure 3).
Single nucleotide polymorphisms in
the HLA-associated genes that reached
genome-wide significance locate to the
intergenic regions LOC442175|ZNF165
(rs149974, OR = 2.2, p = 1.64 × 10–8),
BTNL2|HLA-DRA (rs6932542, OR = 0.5,
p = 2.3 × 10–9; rs5007263, OR = 0.50, p =
2.8 × 10–9; rs5007259, OR = 0.50, p = 2.8 ×
10–9; rs9268507, OR = 0.51, p = 3.67 × 10–9;
rs5007265, OR = 0.51, p = 4.55 × 10–9;
rs4502931, OR = 0.52, p = 1.67 × 10–8;
rs6926737, OR = 0.52, p = 4.28 × 10–9),
the coding region of CCHCR1 (rs130071,
OR = 1.9, p = 8.69 × 10–8) and the intergenic region PSMB9|HLA-DMB
(rs241406, OR = 7.8, p = 7.89 × 10–10).
However, after conditioning on the
HLA-DRB1 alleles, the effects of all significantly associated SNPs in the extended MHC diminished (Figure 2).
The study is underpowered to identify
multiple independent effects without any
prior hypothesis of association. The effects observed over the HLA region are
most likely due to HLA-DRB1, and secondary effects cannot be detected.
Non-HLA Associations
A total of 19 non-HLA SNPs locating
to seven loci reached a statistical significance of p < 5 × 10–5 (see Figure 1,
Table 2), 1 SNP (rs36110812, OR = 1.60)
in the intergenic region LOC38920|RBPJ
on chromosome 4 and four SNPs
(rs12470623, OR = 0.61; rs6752379, OR =
0.61, rs13001315, OR = 0.62; rs11123911,
OR = 0.62) in the intergenic region
LOC100131131|IL1R1 on chromosome 2.
A further five SNPs in the intronic region and three SNPs in the UTR of IRF1
and SNPs in the intronic region of ICOS
(rs6761201, OR = 0.47) and KIAA1542
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Figure 1. Manhattan plot to highlight the Immunochip loci associated with RA in a black South African study. The strongest associations
locate to chromosome 6, the HLA class II loci. Seven non-HLA loci reached statistical significance (p < 5 × 10–5).

(rs12421158, OR = 1.72) reached significance at this level. On chromosome 6,
three SNPs locating to the intergenic
KIAA1919|REV3L and one SNP between
LOC643749 and TRAF3IP2 showed significance independent of the HLA region. At the majority of regions, we saw
a tight cluster of highly correlated vari-

Table 1. The OR and 95% CI of the classical
HLA DRB1 alleles in black South Africans
and Europeans.

HLA-DRB1
allele

Black
South Africans,
OR (95% CI)

Europeans,
OR (95% CI)

*0401
*0404
*0405
*1001
*1101
*1301
*1302

4.0 (2.5–6.5)
6.9 (3.9–12.2)
4.96 (1.6–15.2)
1.8 (1.0–3.3)
0.5 (0.4–0.8)
0.6 (0.4-0.8)
0.6 (0.4–1.0)

4.14 (3.86–4.44)
3.17 (2.83–3.54)
2.31 (1.77–3.01)
2.53 (2.04–3.14)
0.44 (0.38–0.52)
0.28 (0.24–0.33)
0.29 (0.23–0.38)

ants (Figure 3). The LocusZoom plots
might not represent accurate LD patterns in black South Africans, since data
on this population are not available in
the 1000 Genomes Project.
Genomic regions and genes within the
region are shown in the lower panel (Figures 3A–E). The blue lines show recombination rates within each of the regions.
The filled shapes (circles, rectangles and
so on) represent the P value for SNPs in
the region. The shapes signify the function of the SNP based on its localization
with respect to nearby genes. Different
shapes and their functional implications
are summarized in Figure 3F. The purple
SNP represents the SNP, which is
searched for (shown at the top of the
plot) other SNPs in the region are colored depending on their degree of correlation (r2) with the searched SNP. The degrees of correlation were estimated using
LocusZoom on the basis of African population data in the 1000 Genomes Project.
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One SNP, rs874040, locating to the intergenic region LOC389203|RBPJ was
previously associated with RA in Caucasians. In black South Africans, this
SNP reached the statistically significant
level for replication (p = 0.001248, OR =
1.45).
Three other SNPs reached significance in the intergenic regions
LOC100131866|NR5A2 and
NXN|LOC100130876 and in the coding region of ALOX15B; however,
these were isolated SNPs (Supplementary Figure 1) and were therefore not
considered further.
At a significance of p < 5 × 10–4, a further seven new loci were identified (Supplementary Table 2), the intergenic regions CTLA4|ICOS, TNFAIP3|PERP,
RSPH3|TAGAP, IL18RAP|SLC9A4, and
IL1R2|LOC100131131 and the intronic region of IL23R and ILIR1.
This study had more than 80% power
for allele frequencies ≥0.05 to detect effect

RESEARCH ARTICLE

of the SNPs with reasonable frequency
was significantly associated with RA. Although the most highly associated allele
in European populations is monomorphic
(rs2476601 [R620W]) in this study, other
SNPs in and around the PTPN22 gene
did not show association, thereby excluding PTPN22 from making a notable contribution to RA susceptibility in this African cohort.
The strength of association of the significantly associated HLA and non-HLA
SNPs showed similar results in the overall cohort and the seropositive (aCCP
and RF) subgroups (results not shown).

Figure 2. Conditional analyses on the HLA-DRB1 alleles result in diminished effect in the extended MHC.

sizes of 1.9 and higher. Interestingly,
many of the previously associated SNPs
were found to be either monomorphic or
of lower frequency in our study group.

However, despite the small sample size,
we were adequately powered to detect
significance for similar effect sizes for
several SNPs in the PTPN22 gene. None

DISCUSSION
This study is the first large scale genetic
project performed on a non-admixed African population with RA. It confirms that
the strongest genetic association lies in the
HLA class II region of chromosome 6. In
addition, several non-HLA associations
were observed, including SNPs in the intergenic regions LOC389203|RBPJ,
LOC100131131|IL1R1, KIAA1919 |REV3L,
and LOC643749|TRAF3IP2, and SNPs in
the intron and UTR of IRF1 and the in-

Table 2. Non-HLA SNPs that reached a statistical significance of p < 5 × 10–5.
CHR
1
2
2
2
2
2
4
5
5
5
5
5
5
5
5
6
6
6
6
11
17
17

SNP

A1

MAF in cases

MAF in controls

P

OR (95% CI)

rs1325190
rs12470623
rs6752379
rs13001315
rs11123911
rs6761201
rs36110812
rs2405528
rs886286
rs757105
rs2522047
rs2706393
rs2522050
rs2706395
rs2522056
rs173286
rs25638
rs240959
rs71562296
rs12421158
rs7218037
rs9904554

A
A
A
A
A
G
G
A
G
A
A
A
A
T
A
G
I
A
A
A
G
A

0.08
0.34
0.34
0.38
0.38
0.08
0.48
0.17
0.17
0.17
0.16
0.17
0.17
0.17
0.15
0.47
0.47
0.44
0.12
0.47
0.46
0.37

0.17
0.46
0.46
0.50
0.49
0.16
0.37
0.27
0.27
0.27
0.27
0.27
0.27
0.27
0.24
0.36
0.36
0.33
0.20
0.34
0.34
0.27

2.30E-06
2.51E–05
2.51E–05
4.14E–05
4.61E–05
3.45E–05
4.25E–05
2.16E–05
1.72E–05
1.93E–05
1.26E–05
1.93E–05
2.71E–05
1.93E–05
3.42E–05
3.27E–05
3.27E–05
2.73E–05
4.36E–05
3.94E–06
1.45E–05
4.78E–05

0.42
0.61(0.48–0.77)
0.61(0.48–0.77)
0.62 (0.50–0.78)
0.62 (0.50–0.78)
0.47 (0.33–0.68)
1.60 (1.28–2.01)
0.55 (0.41–0.72)
0.54 (0.41–0.72)
0.55 (0.41–0.72)
0.53 (0.40–0.71)
0.55 (0.41–0.72)
0.55 (0.42–0.73)
0.55 (0.40–0.72)
0.54 (0.40–0.72)
1.62 (1.29–2.03)
1.62 (1.29–2.03)
1.64 (1.30–2.06)
0.51 (0.37–0.71)
1.72 (1.36–2.16)
1.66
1.64

Gene

LOC100131866 | NR5A2
LOC100131131 | IL1R1
LOC100131131 | IL1R1
LOC100131131 | IL1R1
LOC100131131 | IL1R1
ICOS
LOC389203 | RBPJ
IRF1
IRF1
IRF1
IRF1
IRF1
IRF1
IRF1
IRF1
KIAA1919 | REV3L
KIAA1919 | REV3L
KIAA1919 | REV3L
LOC643749 | TRAF3IP2
KIAA1542
NXN | LOC100130876
ALOX15B

Region
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intron
Intergenic
Intron
Intron
Intron
Intron
Intron
UTR
UTR
UTR
Intergenic
Intergenic
Intergenic
Intergenic
Intron
Intergenic
Coding
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Figure 3. LocusZoom plots for non-HLA regions associated with RA in black South Africans.
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tronic region of ICOS and KIAA1542. Furthermore, this study showed that variants
of the PTPN22 gene do not confer risk for
RA in black South Africans. This is expected, as the MAF of the lead SNP in this
gene is very low in the black population
(10).
Although none of the significantly associated SNPs in HLA-DRB1 locate to the
coding region, the effect over the HLA
region is very likely due to HLA-DRB1
alleles. Using conditional analysis, this
study was the first to demonstrate that
HLA DRB1 completely explains the risk
for RA in the extended MHC. Unlike in
Caucasians, we found no associations
with HLA B or HLA DPB1 (34–36), although our sample has limited statistical
power to detect these secondary effects
in the MHC.
Numerous HLA-associated SNPs locating to the intergenic regions
BTNL2|HLA-DRA, LOC442175|ZNF165,
PSMB9|HLA-DMB and to the coding region of CCHCR1 reached genome-wide
significance. However, conditional analysis revealed that the effect can largely be
explained by the strong linkage disequilibrium (LD) with HLA-DRB1.
The association of two SNPs close to
the RBPJ gene on chromosome 4,
rs874040 and rs36110812, in the intergenic region LOC389203|RBPJ, are of interest. The former SNP was previously
found to confer a very modest risk (OR =
1.14) for RA in Caucasians (37). The RBPJ
gene, which is essential for the Notch
pathway, controls numerous cell-fate
specification events. The protein encoded
for by the RBPJ gene is a transcriptional
regulator that binds specifically to the
immunoglobulin kappa-type J segment
recombination signal sequence and acts
as both a transcriptional repressor and
activator (38).
Associations with several SNPs in or
near the interleukin 1 receptor, type 1
(IL1R1) and the interferon regulatory
factor 1 (IRF1) gene were found. The
former is part of the toll-like receptor
superfamily and codes for receptors for
interleukin-1α (IL-1α), interleukin-1β
(IL-1β), and interleukin-1 receptor an-

tagonist (IL-1RA). This receptor interacts with molecules such as MyD88,
IRAK1, IRAK4 and TRAF6. Variants of
this gene have been associated with
asthma (39) and with severe hand osteoarthritis (40). Numerous significantly
associated SNPs locate to the IRF1 gene
on chromosome 5, which is responsible
for the activation of interferon α and β.
Knockout mice with deletion of IRF1
had abnormal peripheral blood lymphocytes, specifically decreased CD8–positive T cell and natural killer (NK)
cell numbers and an increase in CD4–positive T cells (41). Although none of
these SNPs have been associated with
RA in other studies, rs2522056 has been
associated with Crohn’s disease (42), an
increase in acute phase response (43)
and fibrinogen levels and, therefore, can
be considered a risk factor for cardiovascular disease (44).
The TRAF3IP2 gene has been associated with the risk of developing psoriasis
(45) and psoriatic arthritis (46); ICOS,
with alopecia areata; KIAA1542, with the
presence of anti-dsDNA antibody postivity in systemic lupus erythematosus (47),
with the function of the intergenic region
between KIAA1919 and REV3L being
unknown.
None of the non-HLA loci previously
associated with RA in Caucasians could
be definitively shown to confer risk for
RA in this study on black South Africans.
The possible reason for the lack of association in this genetically distinct population may be that these loci are truly not
risk loci in the studied population. However, this study was underpowered to detect the modest-to-small effects of many
of these loci. In addition, the data show
that some of the risk variants in Caucasians are nonpolymorphic in black
South Africans, and in others the MAF is
significantly lower. For example, the
well-studied variant rs2476601, which encodes an amino acid change (R620W) in
one of four SH3 domain binding sites in
the PTPN22 molecule, is monomorphic in
this population. Overall, the corroboration of variants associated with RA in
Caucasians with association in this popu-

lation is similar to the findings in the admixed African-American population (48).
Despite the smaller sample size of the
seropositive subgroups (aCCP and RF),
the strength of association of the HLA
and non-HLA SNPs were very similar to
the overall cohort, suggesting that the
subgroups represent a more genetically
homogenous group.
The ancestry informative markers and
principle component analyses (PCA)
showed a distinction of the black South
African RA cases and controls from Caucasians (CEU), West African populations,
that is, Yoruba of Nigeria (YRI) and the
East Africans, the Luhya (LWK) and Maasai (MKK) tribes of Kenya (31). This genetic diversity between Africans is supported by earlier studies of the frequency
of carriers of the shared epitope (SE) alleles. In black South Africans, more than
90% of RA cases carry at least one copy of
the SE alleles (27) compared with a much
lower frequency of 30% in a Cameroonian population in West Africa (28).
Using a high-throughput genotyping
platform such as the Immunochip array
allowed for the identification of admixed
individuals and thus for better quality
control of the dataset where population
structure as a confounder could be
avoided. This study further highlights
that black South Africans are genetically
distinct from populations resident in the
East and West Africa. These findings emphasize the need for a unique reference
set of data for Southern Africans, which
was not available at the start of this
study. Understanding the genomic architecture of the South African population
will allow better study designs considering LD in this population.
CONCLUSION
The overall significance of this study is
that it has given insight into the genetics
of RA in black South Africans. There are
risk loci that have been shown to be
shared among all populations and others
that are specific to this study population.
The Immunochip was designed on the
basis of Caucasian GWAS data and is
therefore not ideally suited for genotyp-
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ing other ethnic groups. Africans differ
from Caucasians and Asians in terms of
their low LD structure and therefore
many more tagging SNPs are required to
cover the African genome (49). Current
genotyping platforms have inadequate
cover of variation in African genomes.
The relatively small sample size meant
that there was inadequate power to detect the modest effects that some
non–HLA-associated loci might confer on
susceptibility for RA in black South
Africans.
This study did not address other causes
of missing heritability such as gene–gene
interaction, gene–environment interaction
and epigenetic factors. Gene–environment
interactions may contribute to the differences in the genetic risk for RA between
Caucasians and black South Africans. Differences in the prevalence of RA have
been reported between rural and urban
black South Africans (50) and this suggests that urban black South Africans are
exposed to some environmental risk factors that rural blacks are not.
Replication of the newly identified RAassociated loci is necessary. There is a
clear need to conduct genetic studies in a
larger sample size of black South Africans
with RA to identify risk variants with
smaller effect sizes. Furthermore a clinical
phenotype has been described in
Africans, “the African variant” which
predominately affects larger joints and
spares the smaller joints of the hand, unlike classic RA observed in Europeans
(51). Performing studies in this subgroup
will shed light on this unique phenotype
with the hope of identifying pathogenic
pathways that may be used to design individualized, targeted therapy.
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